These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy. Costanzo MR; Januzzi JL J Am Coll Cardiol; 2024 Apr; 83(14):1307-1309. PubMed ID: 38569759 [No Abstract] [Full Text] [Related]
7. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: Dabour MS; George MY; Daniel MR; Blaes AH; Zordoky BN JACC CardioOncol; 2024 Apr; 6(2):159-182. PubMed ID: 38774006 [TBL] [Abstract][Full Text] [Related]
8. Time to SGLT2 Inhibitors Initiation in Patients With Heart Failure. Moon J; Udell JA; Chong A; Fang J; Austin PC; Ko DT; Stukel TA; Atzema CL; Booth GL; Tu K; Naimark DMJ; Jackevicius CA J Am Heart Assoc; 2024 Apr; 13(8):e032296. PubMed ID: 38563368 [No Abstract] [Full Text] [Related]
9. Sweet relationship between SGLT2 inhibition and heart failure. Nabeshima Y; Tanaka A; Node K Int J Cardiol; 2024 Sep; 410():132223. PubMed ID: 38830544 [No Abstract] [Full Text] [Related]
10. Time-varying effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: An updated meta-analysis. Zou X; Shi Q; Li S J Evid Based Med; 2024 Mar; 17(1):13-16. PubMed ID: 38465841 [No Abstract] [Full Text] [Related]
11. As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis. Pinney SP; Costanzo MR J Am Coll Cardiol; 2024 Jun; 83(24):2423-2425. PubMed ID: 38866446 [No Abstract] [Full Text] [Related]
12. Sodium-glucose cotransporter-2 inhibition in a CKD patient with severe heart failure treated by high-dose diuretics and peritoneal ultrafiltration: lesson for the clinical nephrologist. Borrelli S; Garofalo C; Liberti ME; Ruotolo C; Capozzi F; Yavorskiy P; De Nicola L J Nephrol; 2024 Jan; 37(1):199-201. PubMed ID: 37707693 [No Abstract] [Full Text] [Related]
13. Summary and Panel Discussion. Butler J; Rich J; Pessah-Pollack R; Anderson JE JACC Heart Fail; 2024 Jun; 12(6S):S10-S11. PubMed ID: 38839135 [TBL] [Abstract][Full Text] [Related]
14. Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care? Gongora CA; Zhang L; Mattei JL; Ruiz-Mori E; Gonzalez-Robledo G; Slipczuk L; Lara J; Cossio-Aranda JE; Badimon J Cardiovasc Drugs Ther; 2024 Jul; ():. PubMed ID: 38958827 [TBL] [Abstract][Full Text] [Related]
15. Research progress on the effects of SGLT2 inhibitors on multiple metabolic disorders in metabolic syndrome. Xu C; Cai X; Qiu X; Zhao L Zhejiang Da Xue Xue Bao Yi Xue Ban; 2024 Jun; ():1-9. PubMed ID: 38899358 [TBL] [Abstract][Full Text] [Related]
16. SGLT2 Inhibitors and Iron: More Than Meets the Eye. Docherty KF JACC Heart Fail; 2023 Nov; 11(11):1623-1625. PubMed ID: 37737759 [No Abstract] [Full Text] [Related]
17. Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers. Lee SA; Riella LV Kidney Int Rep; 2024 Jun; 9(6):1601-1613. PubMed ID: 38899203 [TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibition for outcomes: Is this the panacea? Ferdinand KC; Arora N Am Heart J Plus; 2022 Sep; 21():100159. PubMed ID: 38559750 [TBL] [Abstract][Full Text] [Related]
19. Postpartum cardiomyopathy with congestive heart failure: A case report. Jayte M; Mohamud A; Dubad F SAGE Open Med Case Rep; 2024; 12():2050313X241263761. PubMed ID: 38911174 [TBL] [Abstract][Full Text] [Related]
20. A Response To: Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. Bossi AC; Forloni F; Colombelli PL Diabetes Ther; 2020 Dec; 11(12):3007-3009. PubMed ID: 33052537 [No Abstract] [Full Text] [Related] [Next] [New Search]